PMC:7299399 / 22255-23011
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T102 | 61-68 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T103 | 104-111 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T79 | 180-190 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T80 | 355-363 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T225 | 268-270 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
| T226 | 537-543 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T227 | 547-548 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T228 | 590-591 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T229 | 688-691 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T230 | 729-736 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T138 | 61-68 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T139 | 104-111 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T140 | 557-559 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T95 | 0-756 | Sentence | denotes | Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 336 | 549-559 | Gene | denotes | Phase I/II | |
| 337 | 355-365 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 341 | 180-199 | Disease | denotes | infectious diseases | MESH:D003141 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32519842-32259480-158492 | 268-270 | 32259480 | denotes | 27 |
| 32519842-32259480-158493 | 366-368 | 32259480 | denotes | 27 |